Jason Tardio

Jason Tardio, M.B.A., joined Immunic from Ovid Therapeutics Inc., where he most recently served as Chief Operating Officer since June 2021, after joining the company as Chief Commercial Officer in November 2019. While there, he led all functions of Ovid’s commercial business, with an emphasis in transitioning the company from a pre-commercial entity into a fully integrated and program-oriented commercial enterprise.

Previously, Mr. Tardio served as Vice President, Head of the Multiple Sclerosis Franchise at Novartis AG from September 2018 to November 2019, a business unit with annual revenues of more than $3 billion, where he successfully launched MAYZENT® (siponimod) and was responsible for developing and managing all aspects of the U.S. commercial plan, brand P&L, strategy development and go-to-market modeling for the Novartis MS franchise. Before Novartis, Mr. Tardio spent nine years in positions of increasing responsibility at Biogen Inc., where he most recently served as General Manager, Managing Director for Biogen’s Latin America South affiliate. Earlier at Biogen, Mr. Tardio held a wide range of sales and marketing roles, including positions in global commercial strategy, the U.S. business unit and the international affiliates, where he played a key role in launching both the AVONEX® PEN (interferon beta-1a) and PLEGRIDY® (peginterferon beta-1a) for relapsing forms of MS. Mr. Tardio’s more than two decades of experience in the biopharmaceutical industry began at Wyeth Pharmaceuticals Inc. and Sepracor, Inc., with various roles in sales, sales training and marketing.

He holds a Bachelor of Science from The College of New Jersey and an MBA in Pharmaceutical Marketing from St. Joseph’s University.